These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 793487)

  • 21. Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy.
    Sears HF; Simon R; Rosenberg SA
    Cancer Treat Rep; 1980; 64(4-5):589-97. PubMed ID: 6933004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An animal model for evaluation of antigen-specific dialyzable leukocyte extracts therapy of osteosarcoma.
    Tsang KY; Pan JF; Fudenberg HH
    Clin Immunol Immunopathol; 1987 Mar; 42(3):360-9. PubMed ID: 3470162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinico-immunological studies of 32 cases of bone tumors].
    Franchi F; Russo V; Luzi G; Santori FS; De Chiara N; Aiuti F
    Minerva Med; 1980 Jun; 71(25):1815-22. PubMed ID: 6968049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical treatment of bone tumors in conjunction with microwave-induced hyperthermia and adjuvant immunotherapy. A preliminary report.
    Fan Q; Ma B; Guo A; Li Y; Ye J; Zhou Y; Qiu X
    Chin Med J (Engl); 1996 Jun; 109(6):425-31. PubMed ID: 9206073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
    Kubista B; Trieb K; Blahovec H; Kotz R; Micksche M
    Anticancer Res; 2002; 22(2A):789-92. PubMed ID: 12014651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of selected parameters of cellular immunity in children with osteosarcoma at diagnosis].
    Markiewicz K; Zeman K; Kozar A; Gołębiowska-Wawrzyniak M; Woźniak W
    Med Wieku Rozwoj; 2012; 16(3):212-21. PubMed ID: 23378399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunotherapy of canine osteosarcoma: a historical and systematic review.
    Wycislo KL; Fan TM
    J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer cells for osteosarcoma.
    Tarek N; Lee DA
    Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response.
    Fang X; Jiang C; Xia Q
    Genet Mol Res; 2015 Oct; 14(4):11763-70. PubMed ID: 26436501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre- and postoperative studies of in vitro cell-mediated reactivity in canine osteosarcoma.
    Bech-Nielsen S; Reif JS; Brodey RS
    Am J Vet Res; 1978 Jan; 39(1):87-93. PubMed ID: 272858
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunologic studies in contacts of osteosarcoma in humans and animals.
    Tsang KY; Blakemore WS
    Nature; 1977 Feb; 265(5594):541-2. PubMed ID: 264600
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells.
    Okamoto T; Yamada N; Tsujimura T; Sugihara A; Nishizawa Y; Ueda H; Kashiwamura S; Tsutsui H; Futani H; Maruo S; Okamura H; Terada N
    J Interferon Cytokine Res; 2004 Mar; 24(3):161-7. PubMed ID: 15035849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfer of osteosarcoma-specific cell-mediated immunity in hamsters by rabbit dialyzable leukocyte extracts.
    Tsang KY; Fudenberg HH; Pan JF
    Cell Immunol; 1985 Feb; 90(2):295-302. PubMed ID: 3855389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical study of a patient with lupus vulgaris before and after injection of dialyzable transfer factor.
    Horsmanheimo M; Krohn K; Virolainen M
    J Invest Dermatol; 1977 Jan; 68(1):10-5. PubMed ID: 318672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunocompetence of lymphocytes from osteosarcoma patients.
    McMaster JH; Weinert CR; Dickens DR
    Lancet; 1973 Apr; 1(7806):781-2. PubMed ID: 4120769
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of virus-induced rat osteosarcoma.
    Urovitz EP; Czitrom AA; Langer F; Gross AE; Pritzker PH
    J Bone Joint Surg Am; 1976 Apr; 58(3):308-11. PubMed ID: 1063128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.